Pharmaceutical Investing Auris Medical Closes Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD
Pharmaceutical Investing Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
RETRANSMISSION: Group Eleven to be Featured on Radius Research for a Live Company Pitch, Deep Dive and Q&A Webinar
Freegold Reports Final 2024 Drilling Results from Golden Summit Continuing to Confirm Higher Grade Potential